Skip to content
LodeRx
LODERX BLOG

Guides, research, and straight talk.

What clinicians actually know about peptide therapy, GLP-1s, and TRT — written for patients, reviewed by physicians.

TB-500 vs BPC-157: How Researchers Frame the Differences
Featured· peptides

TB-500 vs BPC-157: How Researchers Frame the Differences

TB-500 and BPC-157 are often grouped together in peptide research discussions. Here is how the compounds differ, what the FDA has said, and what remains unproven.

October 4, 2026
BPC-157 Research Status in 2026: What Clinicians and Regulators Currently Say
peptides

BPC-157 Research Status in 2026: What Clinicians and Regulators Currently Say

BPC-157 is not FDA-approved. Here is what the 2026 Category 2 list change, the PCAC vote, and current clinical literature actually mean for patients.

October 3, 2026
Compounded GLP-1 Maintenance Dosing: What Happens After the Loading Phase
glp-1

Compounded GLP-1 Maintenance Dosing: What Happens After the Loading Phase

What changes when GLP-1 treatment moves from loading to maintenance dosing, how clinicians decide on dose, and what monitoring looks like going forward.

October 2, 2026
GLP-1 Nausea During Titration: What Clinicians Recommend
glp-1

GLP-1 Nausea During Titration: What Clinicians Recommend

Nausea is the most common GLP-1 side effect during dose titration. Here is what clinicians recommend for eating, pacing, and when to call for help.

October 1, 2026
GLP-1 and Muscle Loss: What the Research Says About Preserving Lean Mass
glp-1

GLP-1 and Muscle Loss: What the Research Says About Preserving Lean Mass

GLP-1 medications can reduce lean mass along with fat. Here's what 2026 research shows about protecting muscle through training, protein, and monitoring.

October 1, 2026
Compounded Tirzepatide Shortage Rules in 2026: What Changed and What Stayed the Same
glp-1

Compounded Tirzepatide Shortage Rules in 2026: What Changed and What Stayed the Same

FDA removed tirzepatide from its shortage list in late 2024. Here is what that meant for compounded tirzepatide access heading into 2026, and what did not change.

September 30, 2026
Compounded Testosterone vs. Commercial Formulations: What the Regulatory Pathway Actually Means
trt

Compounded Testosterone vs. Commercial Formulations: What the Regulatory Pathway Actually Means

Compounded testosterone and commercial testosterone travel different regulatory paths. Here is what FDA oversight, 503A rules, and quality checks actually mean for TRT patients.

September 29, 2026
Magnesium and Zinc for Men's Health: What the Evidence Actually Supports
nutrition

Magnesium and Zinc for Men's Health: What the Evidence Actually Supports

A look at what peer-reviewed research says about magnesium and zinc for testosterone, sleep, and recovery in men, and where the evidence stops.

September 27, 2026
TRT and Fertility: What Clinicians Discuss Before Starting Therapy
trt

TRT and Fertility: What Clinicians Discuss Before Starting Therapy

TRT can suppress sperm production. Learn what clinicians ask about fertility goals, sperm banking, and alternatives before starting testosterone therapy.

September 26, 2026
TRT Lab Retest Timing: How Often Clinicians Recheck Levels in the First Year
trt

TRT Lab Retest Timing: How Often Clinicians Recheck Levels in the First Year

How often are TRT labs rechecked in year one? A breakdown of the 6-week, 3-month, 6-month, and 12-month retest cadence clinicians use, and why dose changes reset it.

September 26, 2026
Primary vs Secondary Hypogonadism: How Clinicians Distinguish the Causes of Low Testosterone
trt

Primary vs Secondary Hypogonadism: How Clinicians Distinguish the Causes of Low Testosterone

Low testosterone has two distinct origins. Learn how LH and FSH labs separate primary from secondary hypogonadism and why the distinction changes care.

September 26, 2026
TRT and Liver Function: What Clinicians Monitor and Why
trt

TRT and Liver Function: What Clinicians Monitor and Why

Learn which liver labs clinicians order during TRT, why ALT and AST matter, and what abnormal results can mean for testosterone therapy candidates.

September 26, 2026